The Hypothesis

I suspect that early-stage aging isn't just a linear pile-up of biomarker decline, but a series of systemic instabilities we can track using Cross-Modal Residual Analysis (CMRA). My hypothesis is that the "collective outliers" found in one-class classification models actually stem from a breakdown in the synchronization between blood-based metabolic markers, like p-tau217, and neuro-functional oscillations seen in saccade trajectories or MRI network topology. If we stop treating these residuals as simple noise, we can spot preclinical pathological divergence long before any single marker hits a clinical threshold.

Mechanistic Reasoning

We currently rely on high-accuracy markers like p-tau217 as our primary indicator of molecular pathology. But this purely molecular view overlooks the homeostatic buffer provided by network-level adaptations. I’m proposing that the brain uses a form of "stochastic resonance" to keep functioning even as proteinopathies rise. In this model, sub-threshold functional decline—visible through saccade trajectory deviations—is masked early on by hyper-active metabolic signaling.

Anomaly detection often misses this because it categorizes these compensatory shifts as "normal variance." By using a deep learning architecture that integrates multi-modal neuroimaging and blood markers to specifically analyze residual error, we can pinpoint where systemic compensation fails—the real onset of accelerated aging. If the gap between the predicted molecular state and the observed functional state hits 1.5 standard deviations above the baseline, that’s our signal that compensatory capacity has been exhausted, marking the transition from "at-risk" to active neurodegeneration.

Testability and Falsifiability

To verify this, we have to move away from static prediction and toward longitudinal error-tracking.

1. Validation Protocol: We’ll run a 24-month multi-modal study tracking plasma p-tau217 alongside fMRI network topology and eye-tracking kinematics in asymptomatic adults aged 50–70.
2. Metrics: Our success depends on the "Cross-Modal Anomaly Score" (CMAS). I expect the CMAS to yield an AUC > 0.95 for predicting cognitive decline five years out, beating single-domain neural networks by at least 15% in early-stage precision.
3. Falsification: The hypothesis fails if (a) these systemic residuals don’t correlate with the rate of cognitive decline, or (b) if the residual error looks the same in "healthy" versus "accelerated" aging groups, which would prove that combining these domains offers no predictive advantage over looking at individual biomarkers alone.

This approach sidesteps the standardization challenges common in single-assay tests by focusing on the relationship between signals—a metric that stays invariant even when raw biomarker numbers drift across different populations.